Topics:
Hematologic Malignancies • Pediatric Oncology • Bone Marrow Transplant • Hematology • Chemotherapy • Cytopenia
When using daratumumab in the setting of post-transplant red cell aplasia or post-transplant immune-mediated cytopenias, do you hold the drug for certain ANC parameters?
Answer from: at Academic Institution
Typically, we do not hold until below ANC 500.
Sign in or Register to read more